Published 20 October 2017 TARGET PharmaSolutions announced that Boehringer Ingelheim International has entered into a multi-year strategic partnership for TARGET-NASH. TARGET-NASH is a longitudinal observational study that evaluates patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). To date, TARGET-NASH has enrolled 2,423 patients at … [Read more...]
Alnylam, Vir to jointly advance RNAi therapeutics for infectious diseases
Published 20 October 2017 Alnylam Pharmaceuticals has announced an exclusive licensing agreement with Vir Biotechnology for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus (HBV) infection. As part of this agreement, the companies will advance Alnylam's HBV program and also initiate a research collaboration … [Read more...]
FDA approves Kite’s Car T therapy Yescarta for B-Cell Lymphoma
PBR Staff Writer Published 20 October 2017 Kite Pharma’s chimeric antigen receptor T cell (CAR T) therapy Yescarta (axicabtagene ciloleucel) has been approved by the US Food and Drug Administration for the treatment of relapsed or refractory large B-cell lymphoma in adult patients who had at least two lines of systemic therapy. The FDA approval for Yescarta includes … [Read more...]
Teva seeks FDA approval for migraine drug fremanezumab
View news from other Pharmaceutical sectors: … [Read more...]
Takeda, HemoShear collaborate to develop drugs for liver diseases
Published 18 October 2017 Takeda has collaborated with HemoShear Therapeutics to discover and develop novel therapeutics for liver diseases such as nonalcoholic steatohepatitis (NASH). The partnership will use the HemoShear’s Reveal-Tx proprietary disease modeling platform, which applies principles of physiological blood flow to tissue derived from patients. The platform … [Read more...]